Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Ukraine
NCT ID: NCT02415894
Last Updated: 2016-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
172 participants
OBSERVATIONAL
2015-04-30
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acceptability and Feasibility of a Simplified Medical Abortion Service Delivery in Western Ukraine
NCT02981030
Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Armenia
NCT01766388
Mifepristone and Misoprostol for Midtrimester Termination of Pregnancy in Uzbekistan
NCT02235155
Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered at 78-84 Days Gestation
NCT01856985
Misoprostol for Second Trimester Termination of Pregnancy
NCT00945997
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be willing to undergo surgical completion if necessary
* Have no contraindications to study procedures, according to provider
* Be willing and able to consent to participate in the study
* Be willing to follow study procedures
Exclusion Criteria
* Any contraindications to vaginal delivery, including placenta previa
* Unable to provide consent
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gynuity Health Projects
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tamar Tsereteli, MD, PhD
Role: STUDY_DIRECTOR
Gynuity Health Projects
Galina Maistruk, MD
Role: STUDY_DIRECTOR
Woman Health and Family Planning Charitable Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Odessa Regional Hospital
Odesa, , Ukraine
Poltava City Maternity Hospital
Poltava, , Ukraine
Vinnitsa Regional Hospital
Vinnitsa, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Platais I, Tsereteli T, Maystruk G, Kurbanbekova D, Winikoff B. A prospective study of mifepristone and unlimited dosing of sublingual misoprostol for termination of second-trimester pregnancy in Uzbekistan and Ukraine. BMJ Sex Reprod Health. 2019 Jun 4:bmjsrh-2018-200167. doi: 10.1136/bmjsrh-2018-200167. Online ahead of print.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.